(Corrects name of inhibitor in paragraph two to MEK from MIK)
WASHINGTON, Feb 23 (Reuters) - Novartis AG has wonU.S. antitrust approval to buy GlaxoSmithKline's oncology drugs with conditions, the Federal Trade Commissionsaid on Monday.
To win approval for the $16 billion deal, Novartis agreed todivest assets related to its BRAF and MEK inhibitor drugs, nowin development to fight melanoma and other cancers, the agencysaid. (Reporting by Diane Bartz; Editing by Kevin Drawbaugh, Editingby Franklin Paul)